The American college of cardiology has updated its guidelines for the management of patients with USA/NSTEMI. The most salient updates are the addition of prasugrel as an option (versus clopidogrel) in those undergoing PCI; the use of IIb/IIIa agents only in those that are high risk (+troponin, DM, substantial ST depression) but not in those without these risk factors, on 2 anti-platelet agents, or those with a high risk of bleeding; extending dual anti-platelet therapy beyond 15 months in some patients with a drug eluting stent; and carefully hydrating/limiting contrast in those with renal dysfunction. The full guidelines can be found at (ACC site)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment